Investors Face October Deadline in ARS Pharmaceuticals Fraud Lawsuit

The litigation centers on claims that ARS Pharmaceuticals provided investors with inaccurate projections regarding the inclusion of neffy in CVS Caremark's insurance coverage. While the company expressed confidence that expanded coverage would commence by July 1, 2026—in time for the critical summer and back-to-school allergy seasons—the lawsuit contends these statements were misleading. Plaintiffs argue that the suppression of adverse facts caused the company's stock to trade at artificially inflated prices, resulting in financial losses when the true status of the coverage was revealed.

Rosen Law Firm, which is representing the class, notes that no class has been certified at this time. Investors who purchased securities during the defined period are not automatically represented by counsel and retain the right to select their own legal team or remain as absent class members. Those interested in serving as a lead plaintiff must file their motion with the court before the October 5, 2026, deadline.